Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ALZN
Upturn stock ratingUpturn stock rating

Alzamend Neuro Inc (ALZN)

Upturn stock ratingUpturn stock rating
$2.91
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: ALZN (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

2 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $180

1 Year Target Price $180

Analysts Price Target For last 52 week
$180Target price
Low$2.75
Current$2.91
high$52.65

Analysis of Past Performance

Type Stock
Historic Profit -22.83%
Avg. Invested days 33
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 2.32M USD
Price to earnings Ratio -
1Y Target Price 180
Price to earnings Ratio -
1Y Target Price 180
Volume (30-day avg) 2
Beta -0.28
52 Weeks Range 2.75 - 52.65
Updated Date 06/30/2025
52 Weeks Range 2.75 - 52.65
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -1210.59

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -106.08%
Return on Equity (TTM) -1092.96%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 2223403
Price to Sales(TTM) -
Enterprise Value 2223403
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -3.13
Shares Outstanding 800954
Shares Floating 715917
Shares Outstanding 800954
Shares Floating 715917
Percent Insiders 3.22
Percent Institutions 0.88

Analyst Ratings

Rating 2
Target Price 180
Buy -
Strong Buy 1
Buy -
Strong Buy 1
Hold 1
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Alzamend Neuro Inc

stock logo

Company Overview

overview logo History and Background

Alzamend Neuro, Inc. (ALZN) is a preclinical stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimeru2019s disease, bipolar disorder, major depressive disorder (MDD), and post-traumatic stress disorder (PTSD). It was founded in 2016 and has been primarily engaged in research and development activities.

business area logo Core Business Areas

  • Alzheimer's Disease Therapeutics: Developing AL001, a lithium-delivery system, and AL002, a cell-based therapeutic vaccine.
  • Neuropsychiatric Disorder Therapeutics: Exploring treatments for bipolar disorder, MDD, and PTSD, leveraging the AL001 technology.

leadership logo Leadership and Structure

The leadership team includes Dr. Milton u201cMJu201d Ezzati, CEO; Stephan Jackman, CFO. The company operates with a structure typical of a small, research-focused biopharmaceutical firm, heavily reliant on scientific expertise and clinical development personnel.

Top Products and Market Share

overview logo Key Offerings

  • AL001 (Lithium-Delivery System): A patented ionic cocrystal composed of lithium and L-proline, designed to deliver lithium more efficiently and potentially with fewer side effects. It is in early-stage clinical trials. Market share is currently 0% as the product is not yet commercialized. Competitors include existing lithium treatments from various pharmaceutical companies.
  • AL002 (Cell-Based Therapeutic Vaccine): An autologous dendritic cell immunotherapy designed to treat Alzheimeru2019s disease. It is also in early-stage development. Market share is currently 0% as the product is not yet commercialized. Competitors include other companies developing Alzheimer's vaccines and immunotherapies.

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry, particularly in the areas of Alzheimeru2019s and neuropsychiatric disorders, is characterized by high unmet need and significant market potential. There's intense competition and high regulatory hurdles.

Positioning

Alzamend Neuro is a preclinical stage company aiming to innovate in drug delivery and immunotherapy for neurological disorders. Its competitive advantage hinges on the potential efficacy and safety benefits of its novel technologies, if proven in clinical trials.

Total Addressable Market (TAM)

The TAM for Alzheimer's therapeutics is projected to be in the billions of dollars annually. Alzamend's position is speculative, dependent on clinical trial outcomes, with the potential to capture a significant portion of the market if its products are successful.

Upturn SWOT Analysis

Strengths

  • Novel drug delivery system (AL001)
  • Innovative immunotherapy approach (AL002)
  • Focus on high-need therapeutic areas
  • Strong patent portfolio

Weaknesses

  • Preclinical stage company with no revenue
  • High cash burn rate
  • Reliance on successful clinical trial outcomes
  • Small market capitalization

Opportunities

  • Positive clinical trial results could drive significant stock appreciation
  • Partnerships with larger pharmaceutical companies
  • Government grants and funding opportunities
  • Expansion into other neurological indications

Threats

  • Clinical trial failures
  • Regulatory hurdles
  • Competition from larger, more established companies
  • Difficulty raising capital

Competitors and Market Share

competitor logo Key Competitors

  • LLY
  • ABBV
  • BIIB
  • ACAD
  • AXSM

Competitive Landscape

Alzamend Neuro faces intense competition from larger pharmaceutical companies with significantly more resources and established products. Alzamend relies on innovative science to disrupt the market. They have the first mover advantage on their product.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is characterized by expansion of research and development programs.

Future Projections: Future growth is contingent on successful clinical trial outcomes and regulatory approvals. Analyst projections are highly speculative at this stage.

Recent Initiatives: Recent initiatives include advancing AL001 into clinical trials and continuing preclinical development of AL002.

Summary

Alzamend Neuro is a high-risk, high-reward preclinical stage company focused on innovative treatments for neurological disorders. Its success hinges on positive clinical trial outcomes for its AL001 and AL002 programs. The company faces significant financial challenges due to its cash burn rate, and must navigate intense competition in the pharmaceutical industry, and is highly speculative.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • SEC filings
  • Analyst reports (where available)
  • ClinicalTrials.gov

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and is subject to change. Investing in preclinical stage companies is highly speculative and carries significant risk.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Alzamend Neuro Inc

Exchange NASDAQ
Headquaters Atlanta, GA, United States
IPO Launch date 2021-06-15
CEO & Director Mr. Stephan Jackman
Sector Healthcare
Industry Biotechnology
Full time employees 4
Full time employees 4

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. The company has partnership agreement with Massachusetts General Hospital for the Phase II clinical trial of AL001. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.